Ganoderic acid T

Ganoderic acid T 是一种可从 Ganoderma lucidum mycelia 分离得到的羊毛甾烷三萜类化合物,能诱导线粒体 (Mitochondria) 介导的凋亡 (Apoptosis) 并抑制 DNA 合成,对宫颈癌、肝癌和肺癌具有抗癌活性。
产品编号: MS-U39077 CAS No.: 103992-91-2 分子式: C36H52O8 分子量: 612.79
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Ganoderic acid T 是一种可从 Ganoderma lucidum mycelia 分离得到的羊毛甾烷三萜类化合物,能诱导线粒体 (Mitochondria) 介导的凋亡 (Apoptosis) 并抑制 DNA 合成,对宫颈癌、肝癌和肺癌具有抗癌活性。

生物实验数据

生物活性 Ganoderic acid T is a lanostane triterpenoid isolated from Ganoderma lucidum mycelia that induces mitochondria-mediated apoptosis and inhibits DNA synthesis, exhibiting anticancer activity against cervical, liver, and lung cancers.
体外研究
(In Vitro)

Ganoderic acid T (6-50 μg/mL; 24 h) 可剂量依赖性地抑制癌细胞系 (95-D、SMMC7721、KB-A-1、KB-3-1、HeLa) 和正常细胞系 (HLF、L-02) 的增殖,其中对 95-D 细胞的抑制活性最强 (IC50 = 27.9 μg/mL)。
Ganoderic acid T (2-10 μg/mL; 12 days) 可剂量依赖性地抑制 95-D 细胞的集落形成,其 EC50 为 3.34 μg/mL。
Ganoderic acid T (50 μg/mL; 4-8 h) 可诱导 95-D 细胞发生时间依赖性凋亡。
Ganoderic acid T (25-50 μg/mL; 24 h) 可剂量依赖性地诱导 95-D 细胞发生 G1 期细胞周期阻滞,在 50 μg/mL 处理 24 h 后,有 76% 的细胞处于 G1 期。
Ganoderic acid T (0-40 μM; 24 h) 可强效抑制宫颈癌 HeLa 细胞、肝癌 HepG2 细胞和肺癌 95-D 细胞的活力 (其中 HeLa 细胞的 IC50 为 11.0 μM),且对非肿瘤 MCF-10A 细胞的细胞毒性显著更低。
Ganoderic acid T (5-40 μM; 24 h) 可剂量依赖性地抑制宫颈癌 HeLa 细胞的 DNA 合成。
Ganoderic acid T (5-20 μM; 24 h) 可呈剂量依赖性地将宫颈癌 HeLa 细胞阻滞于 G1 期,并增加亚 G1 期凋亡细胞群,其中 G1 期细胞占比 55.30%,亚 G1 期细胞占比 17.33%,而对非肿瘤 MCF-10A 细胞仅产生极小影响。
Ganoderic acid T (5-20 μM; 24 h) 可剂量依赖性诱导宫颈癌 HeLa 细胞凋亡,而对非肿瘤 MCF-10A 细胞仅造成极低程度的凋亡。

Cell Proliferation Assay

Cell Line: human highly metastatic lung tumor cell line 95-D, human liver tumor cell line SMMC7721, human epidermal cancer cell lines KB-A-1 and KB-3-1, human cervixal cancer cell line HeLa, human normal cell lines HLF (lung) and L-02 (liver)
Concentration: 6-50 μg/mL; 10-50 μg/mL (95-D-specific analysis)
Incubation Time: 24 h
Result: Reduced proliferation of multiple cancer cell lines in a dose-dependent manner, with higher cytotoxicity to 95-D cells than to normal cell lines.
Suppressed 95-D cell viability by 70% at 50 μg/mL after 24 h, with an IC50 of 27.9 μg/mL.

Apoptosis Analysis

Cell Line: human highly metastatic lung tumor cell line 95-D
Concentration: 50 μg/mL
Incubation Time: 4 h, 8 h
Result: Induced apoptosis in 95-D cells in a time-dependent manner.
Increased total apoptotic cell percentage (early + late apoptosis) to 36.5% after 4 h of treatment with 50 μg/mL.
Resulted in apoptosis in ~50% of the cells after 8 h of treatment with 50 μg/mL.

Cell Cycle Analysis

Cell Line: human highly metastatic lung tumor cell line 95-D
Concentration: 25-50 μg/mL
Incubation Time: 24 h
Result: Induced G1 phase cell cycle arrest in 95-D cells in a dose-dependent manner.
Increased the percentage of cells in G1 phase from 48% (control) to 76% at 50 μg/mL for 24 h.
Decreased the percentage of cells in S phase from 37% (control) to 13% at 50 μg/mL for 24 h.

Cell Cycle Analysis

Cell Line: human cervical cancer HeLa cells, non-tumorous human breast epithelial MCF-10A cells
Concentration: 5 μM, 10 μM, 20 μM
Incubation Time: 24 h
Result: Caused dose-dependent accumulation in the G1 phase in HeLa cells: 44.54% at 5 μM, 46.47% at 10 μM, and 55.30% at 20 μM (compared to 42.53% in control).
Induced a dose-dependent increase in the sub-G1 apoptotic population in HeLa cells: 1.52% at 5 μM, 7.47% at 10 μM, and 17.33% at 20 μM (compared to 0.34% in control).
Caused only minimal changes in MCF-10A cells treated with 20 μM: the G1 phase increased slightly to 72.00% (compared to 66.20% in control), and the sub-G1 population only increased to 1.05% (compared to 0.66% in control).

Apoptosis Analysis

Cell Line: human cervical cancer HeLa cells, non-tumorous human breast epithelial MCF-10A cells
Concentration: 5 μM, 10 μM, 20 μM
Incubation Time: 24 h
Result: Caused a dose-dependent increase in total apoptotic cells (early + late) in HeLa cells: 5.25% at 5 μM, 7.75% at 10 μM, and 11.12% at 20 μM (compared to 0.24% in control).
Increased early apoptotic cells to 3.69% and late apoptotic cells to 7.43% at 20 μM (compared to 99.77% viable cells in control).
Caused only minimal apoptosis in MCF-10A cells treated with 20 μM: total apoptotic cells increased slightly to 2.60%, with viable cells remaining at 97.20%.
体内研究
(In Vivo)

Ganoderic acid T (12.5-25 mg/kg;腹腔注射;每日一次;连续 12 天) 可抑制无胸腺小鼠体内肺癌异种移植物的生长。

Animal Model: BALB/c nude (4-week-old male, athymic, specific-pathogen-free, implanted with human highly metastatic lung cancer 95-D cells via two-step xenograft)
Dosage: 12.5 mg/kg; 25 mg/kg
Administration: i.p.; daily; 12 days
Result: Achieved a tumor growth inhibition ratio of ~30% at 12.5 mg/kg.
Achieved a tumor growth inhibition ratio of ~60% at 25 mg/kg.

化学信息

分子量 612.79
分子式 C36H52O8
CAS No. 103992-91-2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础